JERSEY CITY, N.J. - SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology firm engaged in developing medicines to combat drug-resistant infections, today confirmed it is set to receive a $10 million milestone payment from GSK (LON:GSK).
This payment, part of an exclusive license agreement, is tied to the successful completion of clinical studies for the antifungal drug ibrexafungerp.
The company announced the delivery of final clinical study reports for the FURI, CARES, and NATURE studies, which focused on invasive fungal infections, a medical area in need of new treatment options.
According to SCYNEXIS President and CEO David Angulo, M.D., these studies have yielded positive results consistent with previous analyses, and the findings will be shared at an upcoming scientific conference.
SCYNEXIS expects the milestone payment to be made in the third quarter of 2024, as part of a larger agreement potentially worth up to $448 million, which has already seen SCYNEXIS receive $115 million in upfront and milestone payments. Additionally, GSK is set to pay tiered royalties on sales of ibrexafungerp for various indications.
The company also noted the ongoing efforts to reestablish the supply chain for ibrexafungerp and the planned resumption of the Phase 3 MARIO study targeting invasive candidiasis, a serious hospital-acquired condition.
SCYNEXIS's financial position appears strong, with a cash runway extending beyond two years, and plans to advance their next-generation antifungal compound, SCY-247, into clinical trials later this year.
SCYNEXIS's proprietary antifungal platform, fungerps, includes ibrexafungerp, which has been licensed to GSK and has already received FDA approval for two indications, including the treatment of vulvovaginal candidiasis. The company continues to develop its pipeline with additional antifungal assets in pre-clinical and discovery phases.
In other recent news, SCYNEXIS Inc., a pharmaceutical company, reported significant developments at its 2024 Annual Meeting of Stockholders. Shareholders approved several key proposals, including the re-election of all seven directors nominated by the company.
These directors, David Angulo, M.D., Armando Anido, Steven C. Gilman, Ph.D., Ann F. Hanham, Ph.D., David Hastings, Guy Macdonald, and Philippe Tinmouth, will serve until the 2025 Annual Meeting or until their successors are elected and qualified.
Shareholders also ratified the appointment of Deloitte & Touche LLP as the company's independent auditor for the fiscal year ending December 31, 2024. In addition, the executive compensation disclosed in SCYNEXIS's April 2024 proxy statement received a majority vote in favor.
One of the notable approvals was for the SCYNEXIS, Inc. 2024 Equity Incentive Plan, designed to provide equity incentives to employees, consultants, and directors. Despite a number of votes against and abstentions, the plan was approved, signaling recent developments in the company's governance and compensation policies.
InvestingPro Insights
SCYNEXIS, Inc. (NASDAQ:SCYX) has recently garnered attention with its positive clinical study outcomes and the anticipated milestone payment from GSK. An in-depth look at the company's financial health through InvestingPro reveals some noteworthy details. With a market capitalization of $80.28 million, SCYNEXIS is trading at a remarkably low revenue valuation multiple, considering its impressive gross profit margin of 88.97% for the last twelve months as of Q1 2024. This high margin underscores the potential profitability of the company's antifungal drug, ibrexafungerp, and its future prospects.
Moreover, SCYNEXIS holds more cash than debt on its balance sheet, suggesting a solid financial footing as it moves forward with its pipeline development. InvestingPro Tips also highlight that the company's liquid assets exceed short-term obligations, providing further evidence of its financial stability. Additionally, the company's stock has experienced a strong return over the last three months, with a 37.1% price total return, reflecting growing investor confidence.
Interested readers can find additional insights and a total of 11 InvestingPro Tips for SCYNEXIS at InvestingPro. For those looking to delve deeper into the company's metrics and unlock the full range of InvestingPro features, use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.